<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978506</url>
  </required_header>
  <id_info>
    <org_study_id>1447-0002</org_study_id>
    <secondary_id>2021-001717-36</secondary_id>
    <nct_id>NCT04978506</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Oral Doses of BI 1569912 (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel Group Design) With an Optional Posology (Uptitration) Part (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel Group Design) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this trial are to investigate (1) safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2)&#xD;
      tolerability of BI 1569912 in an up-titrating dosing scheme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Identification of potential mutagenic metabolite in human plasma in study 1447-0001&#xD;
  </why_stopped>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">July 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with drug-related adverse events</measure>
    <time_frame>Up to Day 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval of 24 h after administration of the first dose (AUC0-24)</measure>
    <time_frame>At Day 1</time_frame>
    <description>After the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma after the first dose (Cmax)</measure>
    <time_frame>At Day 1</time_frame>
    <description>After the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)</measure>
    <time_frame>Up to Day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)</measure>
    <time_frame>Up to Day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>Up to Day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio based on Cmax,ss (RA,Cmax)</measure>
    <time_frame>Up to Day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio based on AUC0-τ (RA,AUC)</measure>
    <time_frame>Up to Day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1569912 MRD: treatment group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose (MRD) part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1569912 POSO treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posology part (optional)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1569912 MRD: treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose (MRD) part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1569912 MRD: treatment group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose (MRD) part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1569912 MRD: treatment group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple rising dose (MRD) part</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1569912</intervention_name>
    <description>BI 1569912</description>
    <arm_group_label>BI 1569912 MRD: treatment group 1</arm_group_label>
    <arm_group_label>BI 1569912 MRD: treatment group 2</arm_group_label>
    <arm_group_label>BI 1569912 MRD: treatment group 3</arm_group_label>
    <arm_group_label>BI 1569912 MRD: treatment group 4</arm_group_label>
    <arm_group_label>BI 1569912 POSO treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (Blood pressure&#xD;
             (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          -  Age of 18 to 45 years (inclusive)&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          -  Male subjects who meet any of the following criteria from at least 30 days before the&#xD;
             first administration of trial medication until 30 days after trial completion:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. any of the following methods (of female&#xD;
                  partners) plus condom: implants, injectables, combined oral or vaginal&#xD;
                  contraceptives, intrauterine device&#xD;
&#xD;
               -  Sexually abstinent&#xD;
&#xD;
               -  Surgically sterilised (including hysterectomy of female partner)&#xD;
&#xD;
               -  Postmenopausal female partner, defined as at least 1 year of spontaneous&#xD;
                  amenorrhea (in questionable cases a blood sample with follicle stimulating&#xD;
                  hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140&#xD;
             millimetres of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90&#xD;
             mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance, in particular, hepatic parameters (alanine aminotransferase&#xD;
             (ALT), aspartate aminotransferase (AST), total bilirubin) or renal parameters&#xD;
             (creatinine) exceeding the upper limit of normal (ULN) after repeated measurements&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures/ convulsions or stroke), and other relevant neurological or psychiatric&#xD;
             disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or unexplained blackouts&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

